日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

CDK2 inhibitor BLU-222 synergizes with CDK4/6 inhibitors in drug resistant breast cancers through p21/p27 induction

CDK2抑制剂BLU-222通过诱导p21/p27与CDK4/6抑制剂协同作用,治疗耐药性乳腺癌。

Luo, Linjie; Wang, Yan; Bui, Tuyen; Jiang, Xiaoting; Chen, Mei-Kuang; Rao, Xiayu; Mohammadhosseinpour, Sepideh; Li, Mi; Kim, Serena; Kim, Rachel Y; Kamaliasl, Saba; Ulizio, Carmen W; Tsavachidis, Spyros; Navarro-Yepes, Juliana; Kettner, Nicole M; Wingate, Hannah; Meric-Bernstam, Funda; Hunt, Kelly K; Wang, Jing; Faia, Kerrie; Keyomarsi, Khandan

Single-cell RNA sequencing identifies molecular biomarkers predicting late progression to CDK4/6 inhibition in patients with HR+/HER2- metastatic breast cancer.

单细胞 RNA 测序可识别预测 HR+/HER2-转移性乳腺癌患者 CDK4/6 抑制剂治疗后期进展的分子生物标志物

Luo Linjie, Yang Peng, Mastoraki Sofia, Rao Xiayu, Wang Yan, Kettner Nicole M, Raghavendra Akshara Singareeka, Tripathy Debasish, Damodaran Senthil, Hunt Kelly K, Wang Jing, Li Ziyi, Keyomarsi Khandan

FGFR3-induced Y158 PARP1 phosphorylation promotes PARP inhibitor resistance via BRG1/MRE11-mediated DNA repair in breast cancer models

在乳腺癌模型中,FGFR3诱导的Y158 PARP1磷酸化通过BRG1/MRE11介导的DNA修复促进PARP抑制剂耐药性

Chen, Mei-Kuang; Yamaguchi, Hirohito; Gao, Yuan; Xia, Weiya; Chang, Jeffrey T; Hsiao, Yu-Chun; Shegute, Tewodros W; Lin, Zong-Shin; Wu, Chen-Shiou; Wang, Yu-Han; Litton, Jennifer K; Ding, Qingqing; Wei, Yongkun; Chu, Yu-Yi; Meric-Bernstam, Funda; Piwnica-Worms, Helen; Arun, Banu; Rodon Ahnert, Jordi; Liu, Jinsong; Yao, Jun; Chang, Wei-Chao; Wang, Hung-Ling; Tapia, Coya; Albarracin, Constance T; Keyomarsi, Khandan; Wang, Shao-Chun; Wang, Ying-Nai; Hortobagyi, Gabriel N; Lin, Chunru; Yang, Liuqing; Yu, Dihua; Hung, Mien-Chie

IL-6 predicts CDK4/6 inhibitor resistance, identifying STAT3 as a target in HR + /HER2-negative metastatic breast cancer.

IL-6 预测 CDK4/6 抑制剂耐药性,确定 STAT3 为 HR+/HER2 阴性转移性乳腺癌的靶点

Kettner Nicole M, Bui Tuyen N, Navarro-Yepes Juliana, Ghotbaldini Sanaz, Quintela Bethanie, Luo Catherine K, Lam Nghi, Rao Xiayu, Raghavendra Akshara Singareeka, Wang Yan, Azizian Nancy, Kris Eckols T, Kasembeli Moses Makokha, Evans Kurt, Yi Min, Wingate Hannah, Wang Jing, Sahin Aysegul A, Meric-Bernstam Funda, Hunt Kelly K, Damodaran Senthil, Tweardy David J, Tripathy Debu, Keyomarsi Khandan

Targeting CDK2 and other novel cell cycle targets for breast cancer therapy

以 CDK2 和其他新型细胞周期靶点为靶点的乳腺癌治疗

Chen, Mei-Kuang; Luo, Linjie; Massoumi, Nicole; Keyomarsi, Khandan

Low-Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer.

低分子量细胞周期蛋白 E 使三阴性乳腺癌对 PKMYT1 抑制剂敏感

Li Mi, Lulla Amriti R, Wang Yan, Tsavaschidis Spyros, Wang Fuchenchu, Karakas Cansu, Nguyen Tuyen D T, Bui Tuyen N, Pina Marc A, Chen Mei-Kuang, Mastoraki Sofia, Multani Asha S, Fowlkes Natalie W, Sahin Aysegul, Marshall C Gary, Hunt Kelly K, Keyomarsi Khandan

STAT3 protects hematopoietic stem cells by preventing activation of a deleterious autocrine type-I interferon response

STAT3 通过阻止有害的自分泌 I 型干扰素反应的激活来保护造血干细胞。

Patel, Bhakti; Zhou, Yifan; Babcock, Rachel L; Ma, Feiyang; Zal, M Anna; Kumar, Dhiraj; Medik, Yusra B; Kahn, Laura M; Pineda, Josué E; Park, Elizabeth M; Schneider, Sarah M; Tang, Ximing; Raso, Maria Gabriela; Jeter, Collene R; Zal, Tomasz; Clise-Dwyer, Karen; Keyomarsi, Khandan; Giancotti, Filippo G; Colla, Simona; Watowich, Stephanie S

Exploring Novel Frontiers: Leveraging STAT3 Signaling for Advanced Cancer Therapeutics

探索全新领域:利用 STAT3 信号通路进行癌症治疗

Adesoye, Taiwo; Tripathy, Debasish; Hunt, Kelly K; Keyomarsi, Khandan

Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification

WEE1抑制剂Adavosertib治疗CCNE1扩增的难治性实体瘤的多中心II期临床试验

Fu, Siqing; Yao, Shuyang; Yuan, Yuan; Previs, Rebecca A; Elias, Anthony D; Carvajal, Richard D; George, Thomas J; Yuan, Ying; Yu, Lihou; Westin, Shannon N; Xing, Yan; Dumbrava, Ecaterina E; Karp, Daniel D; Piha-Paul, Sarina A; Tsimberidou, Apostolia M; Ahnert, Jordi Rodon; Takebe, Naoko; Lu, Karen; Keyomarsi, Khandan; Meric-Bernstam, Funda

Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial

评估 Alisertib 单药或联合 Fulvestrant 治疗内分泌耐药晚期乳腺癌患者的疗效:TBCRC041 II 期随机临床试验

Haddad, Tufia C; Suman, Vera J; D'Assoro, Antonino B; Carter, Jodi M; Giridhar, Karthik V; McMenomy, Brendan P; Santo, Katelyn; Mayer, Erica L; Karuturi, Meghan S; Morikawa, Aki; Marcom, P Kelly; Isaacs, Claudine J; Oh, Sun Young; Clark, Amy S; Mayer, Ingrid A; Keyomarsi, Khandan; Hobday, Timothy J; Peethambaram, Prema P; O'Sullivan, Ciara C; Leon-Ferre, Roberto A; Liu, Minetta C; Ingle, James N; Goetz, Matthew P